邹小农,贾漫漫,王鑫,支修益.《2020全球癌症报告》要点解读[J].中国胸心血管外科临床杂志,2021(01).

Yu Yinan,Zhao Jianguo,Xu Jiaona,Bai Rui,Gu Zewei,Chen Xialin,Wang Jianfang,Jin Xueying,Gu Gaoyang.Research Progress on the Cardiotoxicity of EGFR-TKIs in Non-Small Cell Lung Cancer.[J].Current treatment options in oncology,2023.

Leah Wells,Angel Qin.Treatment of Non-Small Cell Lung Cancer with Atypical EGFR Mutations.[J].Current treatment options in oncology,2023.

Uryu Kiyoaki,Imamura Yoshinori,Shimoyama Rai,Mase Takahiro,Fujimura Yoshiaki,Hayashi Maki,Ohtaki Megu,Otani Keiko,Hibino Makoto,Horiuchi Shigeto,Fukui Tomoya,Fukai Ryuta,Chihara Yusuke,Iwase Akihiko,Yamada Noriko,Tamura Yukihiro,Harada Hiromasa,Shinozaki Nobuaki,Tsuya Asuka,Fukuoka Masahiro,Minami Hironobu.Stepwise prolongation of overall survival from first to third generation EGFR-TKIs for EGFR mutation-positive non-small-cell lung cancer: the Tokushukai REAl-world Data project (TREAD 01).[J].Japanese journal of clinical oncology,2023.

Wu Xiaowei,Yin Jin,Deng Yu,Zu Yukun.Whole-genome characterization of large-cell lung carcinoma: A comparative analysis based on the histological classification[J].Frontiers in Genetics,2023.

Maimaitituersun Gulinigaer,Abulimiti Burebiguli,Jin Menglong,Dong Xinxin,Fu Zhenyan.Gefitinib Increases the Incidence of QT Prolongation in Patients with Non-Small Cell Lung Cancer.[J].International heart journal,2023.

Han Rui,Guan Youhong,Tang Min,Li Min,Zhang Binbin,Fei Guanghe,Zhou Sijing,Wang Ran.High Expression of PSRC1 Predicts Poor Prognosis in Lung Adenocarcinoma.[J].Journal of Cancer,2023.

Huang HM,Wei Y,Wang JJ,Ran FY,Wen Y,Chen QH,Zhang BF.Epidermal Growth Factor Receptor Mutation Status and the Impact on Clinical Outcomes in Patients with Non-Small Cell Lung Cancer[J].Balkan Journal of Medical Genetics,2022.

Alanazi Wael A.,Alhamami Hussain N.,Alharbi Metab,Alhazzani Khalid,Alanazi Abdulrahman S.,Alsanea Sary,Ali Nemat,Alasmari Abdullah F.,Alanazi Ahmed Z.,Alotaibi Moureq R.,Alswayyed Mohammed.Angiotensin II type 1 receptor blockade attenuates gefitinib-induced cardiac hypertrophy via adjusting angiotensin II-mediated oxidative stress and JNK/P38 MAPK pathway in a rat model[J].Saudi Pharmaceutical Journal,2022.

Kunimasa Kei,Oka Toru,Hara Satoshi,Yamada Noriyuki,Oizumi Satoshi,Miyashita Yoshihiro,Kamada Risa,Funamoto Tomoya,Kawachi Hayato,Kawamura Takahisa,Inoue Takako,Kuhara Hanako,Tamiya Motohiro,Nishino Kazumi,Matsunaga Takashi,Imamura Fumio,Fujita Masashi,Kumagai Toru.Osimertinib is associated with reversible and dose-independent cancer therapy-related cardiac dysfunction[J].Lung Cancer,2020.

Magdalena Zaborowska-Szmit,Maciej Krzakowski,Dariusz M. Kowalski,Sebastian Szmit.Cardiovascular Complications of Systemic Therapy in Non-Small-Cell Lung Cancer[J].Journal of Clinical Medicine,2020.

Søndergaard Lars,Wong Yam-Hong,Reddy Vivek Y.,Boersma Lucas V.A.,Bergmann Martin W.,Doshi Shephal,Kar Saibal,Sievert Horst,Wehrenberg Scott,Stein Kenneth,Holmes David R..Propensity-Matched Comparison of Oral Anticoagulation Versus Antiplatelet Therapy After Left Atrial Appendage Closure With WATCHMAN[J].JACC: Cardiovascular Interventions,2019.

Han Dan,Tan Hui,Sun Chaofeng,Li Guoliang.Amiodarone-induced life-threatening torsade de pointes in an end-stage lung cancer patient receiving gefitinib.[J].Oxford medical case reports,2019.

Sarju Ganatra,Ajay Sharma,Sachin Shah,Ghulam M. Chaudhry,David T. Martin,Tomas G. Neilan,Syed Saad Mahmood,Ana Barac,John D. Groarke,Salim S. Hayek,Saurbha Dani,David Venesy,Richard Patten,Anju Nohria.Ibrutinib-Associated Atrial Fibrillation[J].JACC: Clinical Electrophysiology,2018.

Soria Jean-Charles,Ohe Yuichiro,Vansteenkiste Johan,Reungwetwattana Thanyanan,Chewaskulyong Busyamas,Lee Ki Hyeong,Dechaphunkul Arunee,Imamura Fumio,Nogami Naoyuki,Kurata Takayasu,Okamoto Isamu,Zhou Caicun,Cho Byoung Chul,Cheng Ying,Cho Eun Kyung,Voon Pei Jye,Planchard David,Su Wu-Chou,Gray Jhanelle E,Lee Siow-Ming,Hodge Rachel,Marotti Marcelo,Rukazenkov Yuri,Ramalingam Suresh S.Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer.[J].The New England journal of medicine,2018(2).

Yasushi Yatabe,Keith M. Kerr,Ahmad Utomo,Pathmanathan Rajadurai,Van Khanh Tran,Xiang Du,Teh-Ying Chou,Ma. Luisa D. Enriquez,Geon Kook Lee,Jabed Iqbal,Shanop Shuangshoti,Jin-Haeng Chung,Koichi Hagiwara,Zhiyong Liang,Nicola Normanno,Keunchil Park,Shinichi Toyooka,Chun-Ming Tsai,Paul Waring,Li Zhang,Rose McCormack,Marianne Ratcliffe,Yohji Itoh,Masatoshi Sugeno,Tony Mok.EGFR Mutation Testing Practices within the Asia Pacific Region: Results of a Multicenter Diagnostic Survey[J].Journal of Thoracic Oncology,2015(3).

Mak I Tong,Kramer Jay H,Chmielinska Joanna J,Spurney Christopher F,Weglicki William B.EGFR-TKI, erlotinib, causes hypomagnesemia, oxidative stress, and cardiac dysfunction: attenuation by NK-1 receptor blockade.[J].Journal of cardiovascular pharmacology,2015.

Lynch Donald R,Kickler Thomas S,Rade Jeffrey J.Recurrent myocardial infarction associated with gefitinib therapy.[J].Journal of thrombosis and thrombolysis,2011.

Roy S Herbst,Rafat Ansari,Frederique Bustin,Patrick Flynn,Lowell Hart,Gregory A Otterson,Gordana Vlahovic,Chang-Heok Soh,Paula O'Connor,John Hainsworth.Efficacy of bevacizumab plus erlotinib versus erlotinib alone in advanced non-small-cell lung cancer after failure of standard first-line chemotherapy (BeTa): a double-blind, placebo-controlled, phase 3 trial[J].The Lancet,2011.

Moore Malcolm J,Goldstein David,Hamm John,Figer Arie,Hecht Joel R,Gallinger Steven,Au Heather J,Murawa Pawel,Walde David,Wolff Robert A,Campos Daniel,Lim Robert,Ding Keyue,Clark Gary,Voskoglou-Nomikos Theodora,Ptasynski Mieke,Parulekar Wendy.Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group.[J].Journal of clinical oncology : official journal of the American Society of Clinical Oncology,2007.

Shigenori Kanazawa.Gefitinib Affects Functions of Platelets and Blood Vesselsvia Changes in Prostanoids Balance[J].Clinical and Applied Thrombosis/Hemostasis,2005.